Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP28 | Q96RU2 | 1/20 | 0.68 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | CCR5 | P51681 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 3/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16294248 | 0.88 | USP28 (0.69) | USP28USP25HTTCCR5ALDH1A1 | |
| SCHEMBL16064489 | 0.87 | USP28 (0.57) | USP28USP25HTTCCR5ALDH1A1 | |
| SCHEMBL3416112 | 0.87 | USP28 (0.65) | USP28USP25HTTCCR5ALDH1A1 | |
| SCHEMBL561347 | 0.85 | CCR5 (0.68) | USP28USP25HTTCCR5ALDH1A1 | |
| SCHEMBL15196646 | 0.85 | CCR5 (0.63) | USP28USP25HTTCCR5ALDH1A1 | |
| SCHEMBL30353418 | 0.85 | CCR5 (0.68) | USP28USP25HTTCCR5ALDH1A1 | |
| SCHEMBL30866196 | 0.84 | MEN1 (0.68) | USP28USP25HTTCCR5PTGER1 | |
| SCHEMBL29186218 | 0.84 | MEN1 (0.68) | USP28USP25HTTCCR5PTGER1 | |
| SCHEMBL8406943 | 0.84 | HTR1A (0.65) | USP28USP25HTTCCR5ALDH1A1 | |
| SCHEMBL6213337 | 0.84 | CCR5 (0.73) | USP28USP25HTTCCR5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911353-B2 | Fatty acid synthase inhibitor and application thereof | JIANGNAN UNIVERSITY (CN) | 2024-02-27 | — | — | US | disclosed |
| US-11911353-B2 | Fatty acid synthase inhibitor and application thereof | JIANGNAN UNIVERSITY (CN) | 2024-02-27 | — | — | US | disclosed |
| EP-3490970-B1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2023-09-13 | — | — | EP | disclosed |
| EP-3490970-B1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2023-09-13 | — | — | EP | disclosed |
| US-11401245-B2 | Compositions for the treatment of pulmonary fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2022-08-02 | — | — | US | disclosed |
| US-20210130301-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-05-06 | — | — | US | disclosed |
| CN-110354110-B | Lipase inhibitor and application thereof | 江南大学 | 2021-03-12 | — | — | CN | disclosed |
| US-20210046027-A1 | Fatty Acid Synthase Inhibitor and Application Thereof | JIANGNAN UNIVERSITY (CN) | 2021-02-18 | — | — | US | disclosed |
| US-10919863-B2 | Compositions for the treatment of pulmonary fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-02-16 | — | — | US | disclosed |
| CN-110354110-A | A kind of Fatty synthesis enzyme inhibitor and its application | 江南大学 | 2019-10-22 | — | — | CN | disclosed |
| CN-1193963-A | Aromatic compounds and pharmaceutical compositions containing them | ZENECA LTD (GB) | 1998-09-23 | — | — | CN | disclosed |
| US-5811459-A | PAIN RELIEVERS | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| EP-0847391-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-06-17 | — | — | EP | disclosed |
| EP-0835246-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-15 | — | — | EP | disclosed |
| EP-0773930-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1997-05-21 | — | — | EP | disclosed |
| WO-1997000863-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1997-01-09 | — | — | WO | disclosed |
| WO-1997000864-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1997-01-09 | — | — | WO | disclosed |
| EP-0733033-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
| WO-1996003380-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919863-B2 | Compositions for the treatment of pulmonary fibrosis | ELANE, MMP1, CCL11 | USP28 2794/4885USP25 2857/4885HTT 4592/4885 |
| US-11911353-B2 | Fatty acid synthase inhibitor and application thereof | FASN, SCD, FADS2 | USP28 1679/4885USP25 2017/4885HTT 4757/4885 |
| US-11401245-B2 | Compositions for the treatment of pulmonary fibrosis | ELANE, MMP1, CCL11 | USP28 2794/4885USP25 2857/4885HTT 4592/4885 |
| US-20210046027-A1 | Fatty Acid Synthase Inhibitor and Application Thereof | FASN, SCD, FADS2 | USP28 1679/4885USP25 2017/4885HTT 4757/4885 |
| US-20210130301-A1 | COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS | ELANE, MMP1, CCL11 | USP28 2794/4885USP25 2857/4885HTT 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.